WIN378 for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine the optimal dose of a new medication, WIN378, for individuals with moderate or severe asthma. WIN378 blocks a protein that can cause lung inflammation, potentially improving asthma symptoms and control. Participants will receive either WIN378 or a placebo (an inactive substance) to assess the medication's absorption and safety. This trial suits those with doctor-diagnosed asthma, who experience airflow limitations, and who regularly use asthma medications. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in asthma care.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it mentions that you should be on at least one maintenance asthma controller medication. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that WIN378 is likely to be safe for humans?
Research shows that WIN378 is being tested to help people with asthma by blocking a protein called TSLP, which causes lung inflammation. Early results from other studies indicate that patients have generally tolerated WIN378 well. Since the current research is in phase 2, earlier studies have shown it to be somewhat safe, allowing this stage to focus more on finding the right dose. However, as with any new treatment, more remains to be learned about its safety and effectiveness, so researchers will closely monitor trial participants for any side effects.12345
Why do researchers think this study treatment might be promising for asthma?
Unlike the standard asthma treatments, which often include inhaled corticosteroids and bronchodilators, WIN378 is delivered through subcutaneous injections. This method may offer more sustained and controlled delivery of the medication, potentially improving management of asthma symptoms. Researchers are excited about WIN378 because it represents a novel approach that could enhance convenience for patients who struggle with inhalers and might offer improved efficacy in controlling asthma over time.
What evidence suggests that WIN378 might be an effective treatment for asthma?
Research has shown that blocking a protein called TSLP can improve asthma management. WIN378, a long-lasting medicine that participants in this trial may receive, is designed to achieve this by reducing lung inflammation, potentially controlling asthma symptoms. Previous studies found that targeting TSLP effectively treats asthma and similar conditions. This treatment could lead to better outcomes for asthma patients by reducing the need for frequent doses.23678
Who Is on the Research Team?
Omar Khwaja, MD
Principal Investigator
Windward Bio
Are You a Good Fit for This Trial?
This trial is for adults with moderate or severe asthma. Participants should not have liver disease, acute viral respiratory infections, or other serious pulmonary conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive WIN378 or placebo administered subcutaneously over a 48-week period
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- WIN378
Find a Clinic Near You
Who Is Running the Clinical Trial?
Windward Bio
Lead Sponsor